Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: drdan who wrote (1079)	6/18/1998 12:03:00 AM
From: Jim B	Respond to of 5402

I like where you are going with that statement from the Wall Street Journal.. seems they now need someone else to continue research in this area... now I wonder who they could find that has 30years experience in blood substitutes.. jim

To: drdan who wrote (1079)	6/18/1998 12:35:00 AM
From: Hyrulean King	Respond to of 5402

When i was in the office last week, i did notice some liederhosen on the Dr's coat rack and a berlitz tape called "yodelling for beginners" and a 'Sound of Music' video. Hmmmm

To: drdan who wrote (1079)	6/18/1998 10:05:00 AM
From: Andrew H	Read Replies (2) \| Respond to of 5402

>>Here's a piece of an article from th Wall Street Journal June 3, 1998, by Thomas M. Burton........."BaxterInternational suspended a European trial of its blood substitute........leaving the compan with a 110 million dollar production plant in Switzerland but with no viable product to make there, at least for now...." So......do you think that a large pharma firm is going to have a problem plunking down the 50 million or so Sanguine needs to finish the preclinical testing ? You can see that they waste money on R&d--big money... This should be pocket change for someone << Hope springs eternal...the point here is how very difficult it is to get a blood substitute product through the FDA trials.